


Listing of the Claims:

Please amend the Claims as follows:

Claims 1-13 (Canceled)

Claim 14 (**Currently Amended**): A combination comprising a therapeutically-



effective amount of a cyclooxygenase-2 inhibitor, a leukotriene B₄ receptor antagonist and 15-Deoxyspergualin, wherein the cyclooxygenase-2 inhibitor is selected from **Dupont Dup-697** (5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-thiophene), **Taisho NS-398** (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), meloxicam, flosulide or compounds of Formula I

wherein:

A is a 5- or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo or carbocyclic rings;


R¹ is at least one substituent selected from the group consisting of heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from the group consisting of alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

R² is selected from the group consisting of alkyl, and amino; and

R³ is a radical selected from the group consisting of halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl,

alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl; or a pharmaceutically-acceptable salt thereof.

Claim 15 (**Currently Amended**): A combination comprising a therapeutically-



effective amount of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor antagonist and rapamycin, wherein the cyclooxygenase-2 inhibitor is selected from **Dupont Dup-697** (5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-thiophene), **Taisho NS-398** (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), meloxicam, flosulide or compounds of Formula I

wherein:

A is a 5- or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo or carbocyclic rings;

R¹ is at least one substituent selected from the group consisting of heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from the group consisting of alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

R² is selected from the group consisting of alkyl, and amino; and

R³ is a radical selected from the group consisting of halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl,

alkylaminocarbonyl, N-arylaminoalkyl, N-alkyl-N-arylaminoalkyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl; or a pharmaceutically-acceptable salt thereof.

Claim 16 (Currently Amended): The combination of Claim 14 wherein the leukotriene B4 receptor antagonist is selected from the group consisting of ~~calcitriol~~ 3-[2-[[3-(5-hydroxy-1,5-dimethyl-hexyl)-3a-methyl-1,2,3,3a,4,5,6,7a-octahydroinden-7-ylidene]]ethylidene]-2-methylene-cyclohexane-1,5-diol, ~~ontazolast~~ 2-Benzoxazamine, N-[(1S)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl- (9CI), Bayer Bay-x-4005 Benzeneacetic acid, cyclopentyl-4-(2-quinolinylmethoxy), Ciba-Geigy CGS-25049C Benzamide, 4-[[5-[4-(aminoiminomethyl)phenoxy]pentyl]oxy]-3-methoxy-N,N-bis(1-methylethyl)-, (2Z)-2-butenedioate (1:1) (9CI), ebselen 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (9CI), Leo-Denmark-ETH-615 Benzoic acid, 4-[[[(3-fluorophenyl)methyl][4-(2-quinolinylmethoxy)phenyl]amino]methyl]- (9CI), Lilly-LY-293444 Benzoic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]- (9CI), ~~One-ONO-LB457~~ Benzenepropanoic acid, 2-(4-carboxybutoxy)-6-[[[(5E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]- (9CI), Terumo-TMK-688 Carbonic acid, 4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenyl ethyl ester (9CI), Boehringer-Ingelheim-BI-RM-270 2-Benzoxazamine, N-[(1S)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl- (9CI), Lilly-LY-213024 Benzenepropanoic acid, 5-(3-carboxybenzoyl)-2-(decyloxy)- (9CI), Lilly-LY-264086 9H-Xanthene-4-propanoic acid, 7-carboxy-3-(decyloxy)-9-oxo- (9CI), Lilly-LY-292728 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI), ~~One-ONO-LB457~~ Benzenepropanoic acid, 2-(4-carboxybutoxy)-6-[[[(5E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]- (9CI), Pfizer-15696 Cyclopentanecarboxylic acid, 1-[(3S,4R)-3-[(1,1'-biphenyl)-4-ylmethyl]-3,4-dihydro-

4-hydroxy-2H-1-benzopyran-7-yl]- (9CI), ~~Perdue-Frederick PF 10042 Pyrrolidine, 1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]- (9CI), Rhone-Poulenc Rorer RP 66153 2-Thiopheneheptanoic acid, dimethyl-3-(3-phenylpropyl)- (9CI), SmithKline-Beecham SB-201146 2-Propenoic acid, 3-[6-[[[(3-aminophenyl)sulfinyl]methyl]-3-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-, (2E)- (9CI), SmithKline-Beecham SB-201993 Benzoic acid, 3-[[[[6-[(1E)-2-carboxyethenyl]-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]methyl]thio]methyl]- (9CI), SmithKline-Beecham SB-209247 2-Propenoic acid, 3-[6-[[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-, (2E)- (9CI), Searle SC-53228 2H-1-Benzopyran-2-propanoic acid, 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-, (2S)- (9CI), Shionogi S-2472, Searle SC-52798 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl) phenoxy]propoxy]-3,4-dihydro-8-propyl-, (+)- (9CI), Leo-Denmark SR-2566, Sumitamo SM 15178 β -Alanine, N-[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-pyridinyl]carbonyl]-N-ethyl- (9CI), American Home Product WAY 121006 [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-4'-(2-quinolinylmethoxy)-(9CI).~~

Claim 17 (Currently Amended) The combination of Claim 15 wherein the leukotriene B4 receptor antagonist is selected from the group consisting of ~~calcitriol~~ 3-[2-[[3-(5-hydroxy-1,5-dimethyl-hexyl)-3a-methyl-1,2,3,3a,4,5,6,7a-octahydroinden-7-ylidene]]ethylidene]-2-methylene-cyclohexane-1,5-diol, entazolast 2-Benzoxazolamine, N-[(1S)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl- (9CI), Bayer Bay-x-4005 Benzeneacetic acid, cyclopentyl-4-(2-quinolinylmethoxy), Giba-Geigy CGS-25019C Benzamide, 4-[5-[4-(aminoiminomethyl)phenoxy]pentyl]oxy]-3-methoxy-N,N-bis(1-methylethyl)-, (2Z)-2-butenedioate (1:1) (9CI), ebsselen 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (9CI), Leo-Denmark ETH-615 Benzoic acid, 4-[[[[(3-fluorophenyl)methyl]][4-(2-quinolinylmethoxy)phenyl]amino]methyl]- (9CI), Lilly-LY-293111 Benzoic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]- (9CI), One-ONO-LB457 Benzenepropanoic acid, 2-(4-carboxybutoxy)-6-[[[(5E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]- (9CI),

~~Terumo-TMK-688~~ Carbonic acid, 4-[5-[[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]amino]-5-oxo-1,3-pentadienyl]-2-methoxyphenyl ethyl ester (9CI), ~~Beehringer~~
~~Ingleheim-BI-RM-270~~ 2-Benzoxazamine, N-[(1S)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl- (9CI), ~~Lilly-LY-213024~~ Benzenepropanoic acid, 5-(3-carboxybenzoyl)-2-(decyloxy)- (9CI), ~~Lilly-LY-264086~~ 9H-Xanthene-4-propanoic acid, 7-carboxy-3-(decyloxy)-9-oxo- (9CI), ~~Lilly-LY-292728~~ 9H-Xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo- (9CI), ~~Ono-ONO-LB457~~ Benzenepropanoic acid, 2-(4-carboxybutoxy)-6-[[[(5E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]- (9CI), ~~Pfizer-15696~~ Cyclopentanecarboxylic acid, 1-[(3S,4R)-3-[(1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]- (9CI), ~~Perdue-Frederick-PF-10042~~ Pyrrolidine, 1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]- (9CI), ~~Rhone-Poulenc~~
~~Rorer-RP-66153~~ 2-Thiopheneheptanoic acid, dimethyl-3-(3-phenylpropyl)- (9CI), ~~SmithKline-Beecham-SB-201146~~ 2-Propenoic acid, 3-[6-[[[(3-aminophenyl)sulfinyl]methyl]-3-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]-, (2E)- (9CI), ~~SmithKline~~
~~Beecham-SB-201993~~ Benzoic acid, 3-[[[6-[(1E)-2-carboxyethenyl]-5-[[8-(4-methoxyphenyl)octyl]oxy]-2-pyridinyl]methyl]thio] methyl]- (9CI), ~~SmithKline~~
~~Beecham-SB-209247~~ 2-Propenoic acid, 3-[6-[[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-, (2E)- (9CI), ~~Searle-SC-53228~~ 2H-1-Benzopyran-2-propanoic acid, 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-, (2S)- (9CI), ~~Shionogi-S-2472~~, ~~Searle-SC-52798~~ 2H-1-Benzopyran-2-carboxylic acid, 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(4-thiazolyl)phenoxy]propoxy]-3,4-dihydro-8-propyl-, (+)- (9CI), ~~Leo-Denmark~~
~~SR-2566~~, ~~Sumitamo-SM-15178~~ β -Alanine, N-[[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy) methyl]-2-pyridinyl]carbonyl]-N-ethyl- (9CI), and ~~American~~
~~Home Product-WAY-121006~~ [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-4'-(2-quinolinylmethoxy)-(9CI).